PTGX Q4 2020 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+107.8% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$19M-333.3% margin

Net Income

-$19M-334.3% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-56.9%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$324M

Total Liabilities

$45M

Stockholders' Equity

$280M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$3M	+107.8%
Gross Profit	$6M	$3M	+107.8%
Operating Income	-$19M	-$17M	-8.9%
Net Income	-$19M	-$18M	-7.9%

Revenue Segments

License And Collaborative Revenue

$7M93%

Financial Service Other

$500,0007%